Document is current
Any future updates will be listed below
-
Authors
Sangiorgi, L.
Boarini, M.
Mordenti, M.
Wang, V.
Westerheim, I.
Skarberg, R. T.
Cavaller-Bellaubi, M.
Clancy, James
Pinedo-Villanueva, R.
Lente, E. J. V.
Marchetti, M.
-
Funding
Funding for this research was provided by:
Mereo BioPharma
- License Information
-
More Information
Article History
Received: 14 May 2024
Accepted: 21 August 2024
First Online: 12 September 2024
Declarations
:
: Not applicable.
: Not applicable.
: LS, MB, and MMordenti are employees of IOR and are compensated for their time on the collaboration with Mereo BioPharma. IW is a board leader of OIFE, which receives grants from Mereo Biopharma and other pharma companies. RTS is a volunteer of OIFE and elected patient representative (ePAG) of ERN-BOND. JC is an employee of Mereo BioPharma and may hold Mereo BioPharma stocks. VW is an employee of UBC Late Stage is contracted by Mereo BioPharma. MCB, RPV, EJVL, MMarchetti have no competing interests.
